Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 1.00 |
| ▸ | TDO2 | P48775 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226606 | 1.00 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL31550888 | 1.00 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL31265741 | 1.00 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL5528789 | 1.00 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRMAPT | |
| Hydrochloric Acid SCHEMBL9818269 | 0.99 | IDO1 (0.97) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL24740358 | 0.88 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRMAPT | |
| Hydrochloric Acid SCHEMBL25245762 | 0.87 | IDO1 (0.97) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL6507505 | 0.83 | IDO1 (0.72) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL25762243 | 0.82 | IDO1 (0.70) | IDO1TDO2GSK3BEGFRMAPT | |
| SCHEMBL1520161 | 0.82 | IDO1 (0.69) | IDO1TDO2GSK3BEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20260029406-A1 | PROTEIN IDENTIFICATION VIA PEPTIDE BARCODES | Quantum-Si Incorporated (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260023081-A1 | SOLID PHASE LIBRARY PREPARATION FOR POLYPEPTIDE SEQUENCING | Quantum-Si Incorporated (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260016481-A1 | POLYPEPTIDE SEQUENCING REAGENTS AND METHODS OF USE | Quantum-Si Incorporated (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250369978-A1 | POLYPEPTIDE CLEAVING REAGENTS AND USES THEREOF | Quantum-Si Incorporated (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250341526-A1 | NOVEL DYES | Quantum-Si Incorporated (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4605526-A1 | POLYPEPTIDE CLEAVING REAGENTS AND USES THEREOF | Quantum-Si Incorporated (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605011-A2 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-119998660-A | Compositions and methods for polypeptide analysis | 宽腾矽公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025024572-A1 | PROTEIN QUANTIFICATION, TRACKING, AND IDENTIFICATION VIA PEPTIDE BARCODES | Quantum-Si Incorporated (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260016481-A1 | POLYPEPTIDE SEQUENCING REAGENTS AND METHODS OF USE | ARGLU1, SPPL2B, QPCTL | IDO1 2612/4885TDO2 4263/4885GSK3B 3822/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | IDO1 1672/4885TDO2 3396/4885GSK3B 3097/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | IDO1 1004/4885TDO2 4501/4885GSK3B 1846/4885 |
| US-20260029406-A1 | PROTEIN IDENTIFICATION VIA PEPTIDE BARCODES | MAX, DNMT3A, SET | IDO1 4092/4885TDO2 4362/4885GSK3B 4012/4885 |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | VIP, PRSS1, CTSC | IDO1 851/4885TDO2 4508/4885GSK3B 2064/4885 |
| US-20260023081-A1 | SOLID PHASE LIBRARY PREPARATION FOR POLYPEPTIDE SEQUENCING | SPPL2B, SPPL2A, CTRC | IDO1 1868/4885TDO2 1618/4885GSK3B 3798/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | IDO1 525/4885TDO2 2629/4885GSK3B 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.